CD274 and neoplasm: In this study, we used syngeneic mouse tumor models to investigate the mechanism of action by which PD-L1-negative tumors responded to treatment with an anti-PD-L1 monoclonal antibody (mAb), and we investigated a novel biomarker based on the inferred mechanism of action.